392 related articles for article (PubMed ID: 27371729)
21. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
André F; Cortés J
Breast Cancer Res Treat; 2015 Feb; 150(1):1-8. PubMed ID: 25677745
[TBL] [Abstract][Full Text] [Related]
22. A structure-guided approach to creating covalent FGFR inhibitors.
Zhou W; Hur W; McDermott U; Dutt A; Xian W; Ficarro SB; Zhang J; Sharma SV; Brugge J; Meyerson M; Settleman J; Gray NS
Chem Biol; 2010 Mar; 17(3):285-95. PubMed ID: 20338520
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
Wendt MK; Smith JA; Schiemann WP
Oncogene; 2010 Dec; 29(49):6485-98. PubMed ID: 20802523
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression.
Kong X; Li G; Yuan Y; He Y; Wu X; Zhang W; Wu Z; Chen T; Wu W; Lobie PE; Zhu T
PLoS One; 2012; 7(8):e41523. PubMed ID: 22876288
[TBL] [Abstract][Full Text] [Related]
25. Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
Chi F; Griffiths JI; Nath A; Bild AH
Breast Cancer Res; 2024 Mar; 26(1):54. PubMed ID: 38553760
[TBL] [Abstract][Full Text] [Related]
26. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
[TBL] [Abstract][Full Text] [Related]
27. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling.
Wen S; Hou Y; Fu L; Xi L; Yang D; Zhao M; Qin Y; Sun K; Teng Y; Liu M
Cancer Lett; 2019 Feb; 442():320-332. PubMed ID: 30391782
[TBL] [Abstract][Full Text] [Related]
28. An EGFR/Src-dependent β4 integrin/FAK complex contributes to malignancy of breast cancer.
Tai YL; Chu PY; Lai IR; Wang MY; Tseng HY; Guan JL; Liou JY; Shen TL
Sci Rep; 2015 Nov; 5():16408. PubMed ID: 26549523
[TBL] [Abstract][Full Text] [Related]
29. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.
Kim B; Wang S; Lee JM; Jeong Y; Ahn T; Son DS; Park HW; Yoo HS; Song YJ; Lee E; Oh YM; Lee SB; Choi J; Murray JC; Zhou Y; Song PH; Kim KA; Weiner LM
Oncogene; 2015 Feb; 34(9):1083-93. PubMed ID: 24662823
[TBL] [Abstract][Full Text] [Related]
30. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
31. DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
Dai MD; Wang YL; Fan J; Dai Y; Ji YC; Sun YM; Peng X; Li LL; Wang YM; Duan WH; Ding J; Ai J
Acta Pharmacol Sin; 2021 Sep; 42(9):1498-1506. PubMed ID: 33288861
[TBL] [Abstract][Full Text] [Related]
32. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
[TBL] [Abstract][Full Text] [Related]
33. Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models.
Li Y; Drabsch Y; Pujuguet P; Ren J; van Laar T; Zhang L; van Dam H; Clément-Lacroix P; Ten Dijke P
Breast Cancer Res; 2015 Feb; 17(1):28. PubMed ID: 25849225
[TBL] [Abstract][Full Text] [Related]
34. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
35. Twist induces epithelial-mesenchymal transition and cell motility in breast cancer via ITGB1-FAK/ILK signaling axis and its associated downstream network.
Yang J; Hou Y; Zhou M; Wen S; Zhou J; Xu L; Tang X; Du YE; Hu P; Liu M
Int J Biochem Cell Biol; 2016 Feb; 71():62-71. PubMed ID: 26693891
[TBL] [Abstract][Full Text] [Related]
36. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
37. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.
Akhand SS; Liu Z; Purdy SC; Abdullah A; Lin H; Cresswell GM; Ratliff TL; Wendt M
Cancer Immunol Res; 2020 Dec; 8(12):1542-1553. PubMed ID: 33093218
[TBL] [Abstract][Full Text] [Related]
39. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
40. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
